VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
12
04
2022
received:
19
03
2022
accepted:
14
04
2022
pubmed:
8
5
2022
medline:
28
7
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia (R/R BCP-ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP-ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patients with R/R BCP-ALL were treated with combination of blinatumomab and VANDA (etoposide, cytarabine, mitoxantrone, dexamethasone and asparaginase) regimen. Complete remission (CR) was achieved in 14/17 patient (82%) and 11/17 (65%) were transplanted. One-year leukaemia-free survival was 58.8% for the whole cohort and 90.9% for transplanted patients. These preliminary data suggest that the VANDA-blinatumomab salvage regimen leads to a very high rate of CR and HSCT in suitable patients.
Substances chimiques
Antibodies, Bispecific
0
Antineoplastic Agents
0
blinatumomab
4FR53SIF3A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-527Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Gokbuget N, Dombret H, Ribera J-M, Fielding AK, Advani A, Bassan R. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524-33.
Gökbuget N, Stanze D, Beck J, Diedrich H, Horst H-A, Hüttmann A. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-41.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-47.
Short NJ, Kantarjian HM, Ravandi F, Huang X, Ferrajoli A, Kadia TM. Hyper-CVAD and sequential Blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: results from a phase II study. Blood. 2020;5(136[Supplement 1]):9-11.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-31.
Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153(1):58-65.
Boissel N, Auclerc M-F, Lhéritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(5):774-80.
Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, et al. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021;56(8):1998-2004.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48.
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-59.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet Lond Engl. 2021;398(10299):491-502.
Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, et al. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020;4(10):2308-16.
Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M, et al. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica. 2022.
Bonifacio M, Papayannidis C, Lussana F, Fracchiolla N, Annunziata M, Sica S, et al. Real-world multicenter experience in tumor Debulking prior to Blinatumomab Administration in Adult Patients with Relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Front Oncol. 2021;11:804714.
Wei AH, Ribera J-M, Larson RA, Ritchie D, Ghobadi A, Chen Y, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021;35(8):2220-31.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage Chemoimmunotherapy with Inotuzumab Ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230-4.